

COVAX Global Supply Forecast

June 23, 2021

CEPI



The COVAX Global Supply Forecast aims to provide an up-to-date overview of the supply of safe and effective vaccines to the COVAX Facility. Our goal is to offer economies participating in COVAX as much clarity as possible on when we expect the doses we have secured to start arriving. To this end, we provide both a global overview as well as specific regional forecasts.



According to our forecasting and assuming funding availability, we expect as many as ~1.5 billion doses to be available to the 92 economies of the Gavi COVAX Advance Market Commitment (AMC) in 2021, corresponding to ~23% coverage of AMC populations.¹

There are many uncertainties affecting the supply of COVID-19 vaccines in 2021, not least around manufacturing capacity, regulation, funding availability, final contract terms and the readiness of countries themselves to begin their national COVID-19 vaccination programmes. We list these caveats in the right hand column of each slide.

In recognition of the fast-changing nature of COVAX's supply outlook, and of the need to balance uncertainty with predictability, COVAX is committed to regularly updating this forecast.



¹ India handled exceptionally as decided by the Gavi Board.

COVAX headlines


Key changes since previous forecast

- **COVAX has commitments directly from manufacturers and from dose-sharing countries for ~4.1 billion doses**, of which ~2.8 billion doses are currently secured through legally-binding contracts with manufacturers. **COVAX is in discussions with additional manufacturers for further supply of up to another ~1 billion doses** across 2021 and 2022, which will **take the total to more than 5 billion doses available for supply in 2021 and 2022**.
 - **Of this, COVAX is forecast to have ~1.9 billion doses available for supply by end of 2021**. Of these, **AMC Participants are expected to receive ~1.5 billion doses**, including donated doses, **equivalent to approximately 23% population coverage** (excluding India).
 - **In Q4 2021, COVAX could have supply of ~400M doses per month available, of which ~300M are expected to be available for supply to AMC Participants**. COVAX is working with countries to understand absorptive capacity, identify delivery constraints, and co-create solutions using available COVAX delivery funds.
 - **Expected timing of supply of volumes is based on anticipated date of release from manufacturers**; timing of delivery to countries is likely to be lagged based on necessary prerequisites including local regulatory approvals, supply agreements, and logistics.
 - **These supply forecasts will continue to evolve**; key drivers include confirmation of resumption of exports from India-based manufacturers, timing of regulatory approvals for upcoming candidates such as Novavax, and additional dose-sharing commitments from converting COVAX allocations or by donating surplus volumes from bilateral deals.
-
- Continuing its active portfolio management, **COVAX has signed APAs with three new manufacturers for more than 1 billion doses**: Moderna (500M), Novavax (350M), and J&J (200M). These deals secure substantial volumes for 2021 supply and help COVAX to further diversify its portfolio in terms of vaccine technologies and manufacturing footprint.
 - To boost immediate availability of vaccines, **countries with surplus vaccines have already committed to sharing an additional 515 million doses**, with deliveries from France and New Zealand already underway. COVAX is seeking clarity on remaining donations announced at the G7 Summit.

COVAX Facility candidate-specific supply

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Available Supply, M doses, 2021 and 2022



There are currently eight vaccines in the COVAX portfolio:

1. SII: Covishield ("AZD1222")
2. SII: Covovax ("NVX-CoV2373")
3. Moderna: mRNA 1273
4. Novavax : NVX-CoV2373
5. Janssen J&J²: Ad26COV2.S
6. AstraZeneca: ChAdOx1-S [recombinant] ("AZD1222")
7. Pfizer/BioNTech: BNT162b2
8. Sanofi-GSK: Recombinant Protein

1 "Committed doses" are doses that the COVAX Facility is required to procure. "Optional doses" are doses that the COVAX Facility has the option to procure in the future, but is not required to purchase. Once optional doses are exercised, they become committed doses. For non-binding agreements and deals under active negotiation, the split of committed vs. optional doses will be finalized upon deal signature.

2 COVAX has signed an Advance Purchase Agreement (APA) with Janssen for 200M doses; negotiations for an additional 300M doses are ongoing as per the Memorandum of Understanding [announced](#) on 18 December 2020.

3 "Dose donations" are estimated based upon commitments from donors to share new doses with the COVAX Facility. The transfer of COVAX allocations between COVAX Facility Participants from SFPs to AMC Participants are already included in the volumes secured by COVAX from legally-binding agreements.

4 US support has allowed COVAX to secure an additional 500M Pfizer/BioNTech doses. Reflecting US funding above its original pledge, 200M of these are recorded as a donation.

5 In the following supply forecast slides, volumes for expected single-dose regimen candidates have been doubled to ensure comparability with two-dose candidates.


COVAX Facility global supply forecast

By AMC-eligible and Self-Financing Participants

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Available Supply, Cumulative, M doses, 2021 and 2022¹

■ AMC ■ Max. SFP volume² □ Confirmed dose donations³



CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, export licenses, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

¹ Timing of available supply is based on anticipated date of release of doses from manufacturers. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes have been rounded to nearest 5M, except those less than 10M, and so totals may not equal sum of segments.

² Final SFP volumes may be lower than forecasted based on opt-out and dose-sharing behavior. Volumes only account for current SFP demand based on Commitment Agreements.

³ “Dose donations” are estimated based upon commitments from donors to share new doses with COVAX. The transfer of COVAX allocations between COVAX Participants from SFPs to AMC Participants are already included in the AMC Participant volumes. Total donations on this chart are larger than 515M due to doubling of single-dose candidates.


COVAX Facility global supply forecast

Supply from signed agreements vs. Supply under active negotiation

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Available Supply, Cumulative, M doses, 2021 and 2022¹

■ Supply from signed agreements² ■ Volumes under active negotiation □ Confirmed dose donations³



Potential volumes currently available, assuming all deals under negotiation are signed and all options are exercised, subject to funding availability¹

Reflects COVAX deliveries to date

¹ Timing of available supply is based on anticipated date of release of doses from manufacturers. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes have been rounded to nearest 5M, except those less than 10M, and so totals may not equal sum of segments.

² "Signed agreements": Legally-binding agreements, memoranda of understanding, and statements of intent.

³ "Dose donations" are estimated based upon commitments from donors to share new doses with COVAX. The transfer of COVAX allocations between COVAX Participants from SFPs to AMC Participants are already included in "Supply from signed agreements". Total donations on this chart are larger than 515M due to doubling of single-dose candidates.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches ("batch release").

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, export licenses, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.


Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant's share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

COVAX Facility global supply forecast

By WHO region

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Available Supply, Cumulative, M doses, 2021 and 2022¹



CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, export licenses, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

¹ Timing of available supply is based on anticipated date of release of doses from manufacturers. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes have been rounded to nearest 5M, except those less than 10M, and so totals may not equal sum of segments.

WHO region-specific supply forecasts


COVAX Facility supply forecast

AFRO Region

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Available Supply, Cumulative, M doses, 2021 and 2022¹

■ AMC ■ Max. SFP volume² □ Confirmed dose donations³



CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, export licenses, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

¹ Timing of available supply is based on anticipated date of release of doses from manufacturers. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes have been rounded to nearest 5M, except those less than 10M, and so totals may not equal sum of segments.
² Final SFP volumes may be lower than forecasted based on opt-out and dose-sharing behavior. Volumes only account for current SFP demand based on Commitment Agreements.
³ “Dose donations” are estimated based upon commitments from donors to share new doses with COVAX. The transfer of COVAX allocations between COVAX Participants from SFPs to AMC Participants are already included in the AMC Participant volumes.


COVAX Facility supply forecast

EMRO Region

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Available Supply, Cumulative, M doses, 2021 and 2022¹

■ AMC ■ Max. SFP volume² □ Confirmed dose donations³



CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, export licenses, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

¹ Timing of available supply is based on anticipated date of release of doses from manufacturers. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes have been rounded to nearest 5M, except those less than 10M, and so totals may not equal sum of segments.
² Final SFP volumes may be lower than forecasted based on opt-out and dose-sharing behavior. Volumes only account for current SFP demand based on Commitment Agreements.
³ “Dose donations” are estimated based upon commitments from donors to share new doses with COVAX. The transfer of COVAX allocations between COVAX Participants from SFPs to AMC Participants are already included in the AMC Participant volumes.


COVAX Facility supply forecast

EURO Region

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Available Supply, Cumulative, M doses, 2021 and 2022¹

■ AMC ■ Max. SFP volume² □ Confirmed dose donations³



¹ Timing of available supply is based on anticipated date of release of doses from manufacturers. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes have been rounded to nearest 5M, except those less than 10M, and so totals may not equal sum of segments.
² Final SFP volumes may be lower than forecasted based on opt-out and dose-sharing behavior. Volumes only account for current SFP demand based on Commitment Agreements.
³ "Dose donations" are estimated based upon commitments from donors to share new doses with COVAX. The transfer of COVAX allocations between COVAX Participants from SFPs to AMC Participants are already included in the AMC Participant volumes.

CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches ("batch release").

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, export licenses, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant's share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.


COVAX Facility supply forecast

PAHO Region

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Available Supply, Cumulative, M doses, 2021 and 2022¹

■ AMC ■ Max. SFP volume² □ Confirmed dose donations³



CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, export licenses, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

¹ Timing of available supply is based on anticipated date of release of doses from manufacturers. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes have been rounded to nearest 5M, except those less than 10M, and so totals may not equal sum of segments.
² Final SFP volumes may be lower than forecasted based on opt-out and dose-sharing behavior. Volumes only account for current SFP demand based on Commitment Agreements.
³ “Dose donations” are estimated based upon commitments from donors to share new doses with COVAX. The transfer of COVAX allocations between COVAX Participants from SFPs to AMC Participants are already included in the AMC Participant volumes.


COVAX Facility supply forecast

SEARO Region

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Available Supply, Cumulative, M doses, 2021 and 2022¹

■ AMC ■ Max. SFP volume² □ Confirmed dose donations³



CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, export licenses, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

¹ Timing of available supply is based on anticipated date of release of doses from manufacturers. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes have been rounded to nearest 5M, except those less than 10M, and so totals may not equal sum of segments.
² Final SFP volumes may be lower than forecasted based on opt-out and dose-sharing behavior. Volumes only account for current SFP demand based on Commitment Agreements.
³ “Dose donations” are estimated based upon commitments from donors to share new doses with COVAX. The transfer of COVAX allocations between COVAX Participants from SFPs to AMC Participants are already included in the AMC Participant volumes.


COVAX Facility supply forecast

WPRO Region

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Available Supply, Cumulative, M doses, 2021 and 2022¹

■ AMC ■ Max. SFP volume² □ Confirmed dose donations³



CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, export licenses, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

¹ Timing of available supply is based on anticipated date of release of doses from manufacturers. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes have been rounded to nearest 5M, except those less than 10M, and so totals may not equal sum of segments.
² Final SFP volumes may be lower than forecasted based on opt-out and dose-sharing behavior. Volumes only account for current SFP demand based on Commitment Agreements.
³ “Dose donations” are estimated based upon commitments from donors to share new doses with COVAX. The transfer of COVAX allocations between COVAX Participants from SFPs to AMC Participants are already included in the AMC Participant volumes.

Other views of COVAX supply forecast


COVAX Facility supply forecast

African Union

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Available Supply, Cumulative, M doses, 2021 and 2022¹

■ AMC ■ Max. SFP volume² □ Confirmed dose donations³



CAVEATS

Contracts: Some of the supply included in the projections are linked to deals that are already concluded and some are currently being negotiated. Terms are subject to change.

Candidate attrition: Some candidates are still in clinical development. If they do not achieve positive clinical trial outcomes (safety and efficacy) and regulatory approval, these volumes will not be procured by COVAX.

Regulatory approval: Supply timing will depend on regulatory success and timelines, including reviews of individual batches (“batch release”).

Manufacturing: In many cases, manufacturing is yet to reach full scale. Manufacturing productivity will be influenced by multiple factors, which will in turn influence volume and timing of supply.

Delivery: Timing of delivery will depend on various factors, including local regulatory approval, country readiness, export licenses, logistics, indemnification and liability in place, in-country distribution etc.

Funding availability: Total potential supply is shown; procurement of these doses will depend on COVAX AMC fundraising, AMC92 cost-sharing beyond donor-funded doses, and the final prices and volumes of doses allocated to AMC92.

Allocation: These supply forecasts reflect a preliminary distribution of doses based on each participant’s share of available supply pro rata by demand and are to be treated as indicative. Final timing and volumes will be determined by the WHO Allocation Mechanism.

¹ Timing of available supply is based on anticipated date of release of doses from manufacturers. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes have been rounded to nearest 5M, except those less than 10M, and so totals may not equal sum of segments.
² Final SFP volumes may be lower than forecasted based on opt-out and dose-sharing behavior. Volumes only account for current SFP demand based on Commitment Agreements.
³ “Dose donations” are estimated based upon commitments from donors to share new doses with COVAX. The transfer of COVAX allocations between COVAX Participants from SFPs to AMC Participants are already included in the AMC Participant volumes.

COVAX

CEPI



Thank you